A Phase 3 interventional study of tacrolimus and mycophenolate mofetil in Atherosclerosis and Kidney Failure, sponsored by Pfizer. Terminated at 8 sites in 2 countries. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2013-09-23.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies in Atherosclerosis with a site in Canada — 10 open to participants now, 17 under way, 9 of them phase 3. Atherosclerosis · Canada.
Among the 91 studies in Atherosclerosis with a site in Canada, this one is the 65th largest by enrollment of the 73 interventional ones that give a count, is one of 3 that started in 2006, is one of 31 in phase 3, and was the 18th registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →10 of the 91 studies in Atherosclerosis with a site in Canada are open now. Recruiting first, the newest first:
Beijing Inno Medicine Co., Ltd. · Sites in Canada, United States, Australia and 1 more country
Ages 18–80
Genentech, Inc. · Sites in Canada, United States
Ages 18+
University of Alberta · Sites in Canada
Ages 25–45 · Women only
Eli Lilly and Company · Sites in Canada, United States, Argentina and 25 more countries
Ages 18+
AstraZeneca · Sites in Canada, United States, Argentina and 33 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: 35 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 17 · Phase 3 34 · Phase 4 6
First in 1999; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is below the median of 100 across 881 interventional studies indexed under Atherosclerosis.
Median enrollment 440 across the 73 interventional studies, 341 across the 18 observational. Of the 64 that completed or were terminated, 30 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 91 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 1 study filed under Atherosclerosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Atherosclerosis with a site in Canada that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05202509Phase 3NewAmsterdam PharmaCardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | 2026-11 |
| NCT07000123Phase 3AstraZenecaA Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event | 2027-01-11 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT06424860University of AlbertaFish Oil, Metformin and Heart Health in PCOS | 2026-12-30 |
| NCT07521007Beijing Inno Medicine Co., Ltd.A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis | 2027-07-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 91 studies in Atherosclerosis with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether immunosuppression by tacrolimus, mycophenolate mofetil, and prednisone compared to conversion to sirolimus, mycophenolate mofetil, and prednisone affect the progression of atherosclerosis in renal transplant recipients.
A decision to terminate the study was taken in November 2011 and a communication to that effect sent to all participating sites on November 18. All sites were asked to have patients returned to the sites and have all end of study procedures performed by Dec 31, 2011.
The decision to terminate this study was made following the conduct of an interim analysis which demonstrated that the study did not reach its primary endpoint. The termination of this study was not driven by any safety concerns and had no impact on subject safety and well-being.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At least one of the following characteristics:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tacrolimus + MMF + Steroids
Drug: tacrolimus · Drug: mycophenolate mofetil · Drug: prednisone
Tacrolimus + MMF + Steroids with conversion from Tacrolimus to Sirolimus at 3-4 months post-transplant
Drug: sirolimus · Drug: tacrolimus · Drug: mycophenolate mofetil · Drug: prednisone
The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. The target trough level of TAC will be maintained at 3-10 ng/mL through to the end of the study.
Also known as: CNI
The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.
Also known as: MMF, MPS
The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.
Also known as: CCS
The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol. On study Day 1 Conversion, the daily dose of TAC will not be taken, and SRL is initiated as a single 5-10 mg loading dose, followed by 3 mg/day on subsequent days, adjusted to maintain a SRL target trough level of 8-15 ng/mL through to month 24 post-transplant, then 5-12 ng/mL to the end of month 36 post-transplant.
The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. Reintroduction of TAC or introduction of CsA is not permitted in the SRL Therapy group.
Also known as: CNI
The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.
Also known as: MMF, MPS
The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.
Also known as: CCS
Annual Change Rate in Total Plaque Volume (TPV) From Pre-conversion Baseline to 12 Months Post-transplant
Within-subject annual change rate in TPV in the left and right distal common carotid arteries from the pre-conversion baseline to 12 months post kidney transplant as determined by ultrasound. Annual change rate equals (=) (TPV at month 12 post-transplant minus \[-\] TPV at pre-conversion baseline) divided (/) by imaging interval in years. TPV is the sum of assessment in left and right distal common carotid arteries.
Time frame: Pre-conversion baseline and 12 months post-transplant
TPV at Pre-conversion Baseline
TPV is the sum of the assessment in left and right distal common carotid arteries.
Time frame: Pre-conversion baseline
Annual Change Rate in Carotid Intima Media Thickness (CIMT) From Pre-conversion Baseline at 12, 18, 24 and 36 Months Post-transplant
Within-subject annual change rate in CIMT as determined by ultrasound. Mean CIMT=average of left CIMT and right CIMT. Annual CIMT Change Rate (mm/year) = (CIMT at Month x Post-transplant Visit - CIMT at Conversion Baseline) / Imaging interval in years.
Time frame: Pre-conversion baseline, and 12, 18, 24 and 36 months post-transplant
CIMT at Pre-conversion Baseline
Mean CIMT=average of left CIMT and right CIMT.
Time frame: Pre-conversion baseline
Change From Pre-conversion Baseline in Carotid Plaque Roughness at 12 and 24 Months Post-transplant
Carotid plaque roughness as determined by ultrasound. Change equals (=) value at post-transplant month x minus (-) pre-conversion baseline.
Time frame: Pre-conversion baseline, 12, and 24 months post-transplant
Change From Pre-conversion Baseline in Fasting Lipid Parameters at 12, 18, 24 and 36 Months Post-transplant
Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL) and Triglyceride (Tg) blood concentrations. Higher levels of TC, LDL and Tg are less desirable. Lower levels of HDL are less desirable. Change for each parameter = value at 12, 18, 24 and 36 months post-transplant - value at pre-conversion baseline.
Time frame: Pre-conversion baseline, and 12, 18, 24 and 36 months post-transplant
Change From Pre-conversion Baseline in Glucose at Months 12, 24 and 36 Post-transplant
Fasting plasma glucose. Change = value at month x post-transplant - pre-conversion baseline values.
Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant
Change From Pre-conversion Baseline in Insulin at Months 12, 24, and 36 Post-transplant
Fasting insulin. Change = value at month x post-transplant - pre-conversion baseline.
Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant
Change From Pre-conversion Baseline in Glycosylated Hemoglobin(HbA1C) at Months 12, 24, and 36 Post-transplant
HbA1C, change = value at month x post-transplant - pre-conversion baseline.
Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant
Change From Pre-conversion Baseline in Adiponectin at Months 12, 24 and 36 Post-transplant
Adiponectin is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates less risk. Change = month x post-transplant values - pre-conversion baseline values.
Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant
Change From Pre-conversion Baseline in High Sensitivity C-Reactive Protein (hsCRP) at Months 12, 24 and 36 Post-transplant.
hsCRP is a biomarker of cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.
Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant
Change From Pre-conversion Baseline in Tumor Necrosis Factor Alpha (TNF-alpha) at Months 12, 24 and 36 Post-transplant
TNF-alpha is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.
Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant
Change From Pre-conversion Baseline in Endothelin-1 at Months 12, 24 and 36 Post-transplant
Endothelin-1 is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates greater risk. Change = month x post-transplant values - pre-conversion baseline values.
Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant
Change From Pre-conversion Baseline in Interleukin-6 (IL-6) at Months 12, 24 and 36 Post-transplant
IL-6 is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion values.
Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant
Change From Pre-conversion Baseline in Homocysteine at Months 12, 24 and 36 Post-transplant
Homocysteine is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.
Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant
Change From Pre-conversion Baseline in Lipoprotein(a) at Months 12, 24 and 36 Post-transplant
Lipoprotein(a) is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.
Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant
Change From Pre-conversion Baseline in Fibrinogen at Months 12, 24 and 36 Post-transplant
Fibrinogen is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.
Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant
Change From Pre-conversion Baseline in Vitamin B12 at Months 12, 24 and 36 Post-transplant
Vitamin B12 is a biomarker for cardiovascular disease and atherosclerosis risk. A lower level indicates a greater risk. Change = month x post-transplant values - pre-conversion values.
Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant
Change From Pre-conversion Baseline in Uric Acid at Months 12, 24 and 36 Post-transplant
Uric Acid is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.
Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant
Change From Pre-conversion Baseline in Folate at 12, 24 and 36 Months Post-transplant
Folate is a biomarker for cardiovascular disease and atherosclerosis risk. A lower level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.
Time frame: Pre-conversion baseline, 12, 24 and 36 months post-transplant
Number of Participants Who Used Lipid Lowering Therapies
Participants who reported "yes" for taking lipid lowering therapies as concomitant medication.
Time frame: From consent to conversion, from conversion to Month 12, from Months 12 to 24, and from Months 24 to 36 post-transplant
Number of Participants Who Used Anti-hypertensive Medications
Participants who reported "yes" for taking anti-hypertensive medications as concomitant medication.
Time frame: From consent to conversion, from conversion to Month 12, from Months 12 to 24, and from Months 24 to 36 post-transplant
Annual Rate of Change in TPV From Pre-conversion Baseline to 18, 24 and 36 Months Post Transplant
Within-subject annual change rate in TPV in the left and right distal common carotid arteries from the pre-conversion baseline to 18, 24 and 36 months post kidney transplant as determined by ultrasound. Annual change rate equals (=) (TPV at month 18, 24 and 36 post-transplant minus \[-\] TPV at pre-conversion baseline) divided (/) by imaging interval in years. TPV is the sum of assessment in left and right distal common carotid arteries.
Time frame: Pre-conversion baseline, and 18, 24 and 36 months post-transplant
| Milestone | Tacrolimus Then Sirolimus With Mycophenolate/Prednisone | Tacrolimus With Mycophenolate/Prednisone |
|---|---|---|
| Started | 37 | 35 |
| Completed | 29 | 26 |
| Not completed | 8 | 9 |
| Withdrew: Adverse event | 3 | 2 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Noncompliance | 0 | 1 |
| Withdrew: Study termination by sponsor | 3 | 4 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lack of ancillary assistance | 0 | 1 |
Within-subject annual change rate in TPV in the left and right distal common carotid arteries from the pre-conversion baseline to 12 months post kidney transplant as determined by ultrasound. Annual change rate equals (=) (TPV at month 12 post-transplant minus \[-\] TPV at pre-conversion baseline) divided (/) by imaging interval in years. TPV is the sum of assessment in left and right distal common carotid arteries.
| millimeter cube/year (mmˆ3/year) | Tacrolimus Then Sirolimus With Mycophenolate/Prednisone | Tacrolimus With Mycophenolate/Prednisone |
|---|---|---|
| Annual Change Rate in Total Plaque Volume (TPV) From Pre-conversion Baseline to 12 Months Post-transplant | -49.31 ± 125.038 | 0.66 ± 23.103 |
TPV is the sum of the assessment in left and right distal common carotid arteries.
| mmˆ3 | Tacrolimus Then Sirolimus With Mycophenolate/Prednisone | Tacrolimus With Mycophenolate/Prednisone |
|---|---|---|
| TPV at Pre-conversion Baseline | 68.68 ± 116.574 | 48.57 ± 72.207 |
Within-subject annual change rate in CIMT as determined by ultrasound. Mean CIMT=average of left CIMT and right CIMT. Annual CIMT Change Rate (mm/year) = (CIMT at Month x Post-transplant Visit - CIMT at Conversion Baseline) / Imaging interval in years.
| millimeter/year (mm/year) | Tacrolimus Then Sirolimus With Mycophenolate/Prednisone | Tacrolimus With Mycophenolate/Prednisone |
|---|---|---|
| Annual Change Rate at 12 months (n=16,28) | 0.048 ± 0.0977 | 0.012 ± 0.0732 |
| Annual Change Rate at 18 months (n=15,26) | 0.041 ± 0.0641 | -0.0002 ± 0.0543 |
| Annual Change Rate at 24 months (n=15,23) | 0.023 ± 0.0614 | 0.015 ± 0.0453 |
| Annual Change Rate at 36 months (n=8,13) | 0.028 ± 0.0381 | -0.007 ± 0.0460 |
Mean CIMT=average of left CIMT and right CIMT.
| mm | Tacrolimus Then Sirolimus With Mycophenolate/Prednisone | Tacrolimus With Mycophenolate/Prednisone |
|---|---|---|
| CIMT at Pre-conversion Baseline | 0.735 ± 0.1502 | 0.773 ± 0.1391 |
Carotid plaque roughness as determined by ultrasound. Change equals (=) value at post-transplant month x minus (-) pre-conversion baseline.
No measurements were reported for this outcome.
Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL) and Triglyceride (Tg) blood concentrations. Higher levels of TC, LDL and Tg are less desirable. Lower levels of HDL are less desirable. Change for each parameter = value at 12, 18, 24 and 36 months post-transplant - value at pre-conversion baseline.
| millimole/liter (mmol/L) | Tacrolimus Then Sirolimus With Mycophenolate/Prednisone | Tacrolimus With Mycophenolate/Prednisone |
|---|---|---|
| Change in TC 12 Months post-transplant (n=23,30) | 0.510 ± 1.0743 | -0.164 ± 0.8271 |
| Change in LDL 12 Months post-transplant (n=21,30) | 0.277 ± 0.8282 | -0.056 ± 0.5612 |
| Change in HDL 12 Months post-transplant (n=23,30) | 0.059 ± 0.3009 | -0.053 ± 0.4417 |
| Change in Tg 12 Months post-transplant (n=23,30) | 0.617 ± 1.1135 | -0.117 ± 0.6088 |
| Change in TC 18 Months post-transplant (n=21,29) | 0.361 ± 1.0704 | 0.082 ± 1.1427 |
| Change in LDL 18 Months post-transplant (n=20,29) | 0.222 ± 0.9283 | 0.138 ± 0.8600 |
| Change in HDL 18 Months post-transplant (n=21,29) | 0.106 ± 0.2824 | -0.030 ± 0.3601 |
| Change in Tg 18 Months post-transplant (n=21,29) | 0.359 ± 0.9941 | -0.057 ± 0.8699 |
| Change in TC 24 Months post-transplant (n=19,27) | 0.240 ± 1.1375 | -0.008 ± 1.0813 |
| Change in LDL 24 Months post-transplant (n=16,27) | 0.067 ± 0.9493 | 0.054 ± 0.8250 |
| Change in HDL 24 Months post-transplant (n=19,27) | 0.067 ± 0.2485 | -0.019 ± 0.3552 |
| Change in Tg 24 Months post-transplant (n=19,27) | 0.547 ± 1.4083 | -0.088 ± 0.8131 |
| Change in TC 36 Months post-transplant (n=15,21) | 0.386 ± 0.4841 | -0.323 ± 1.0652 |
| Change in LDL 36 Months post-transplant (n=13,21) | 0.027 ± 0.5619 | -0.257 ± 0.8248 |
| Change in HDL 36 Months post-transplant (n=15,21) | 0.098 ± 0.2141 | 0.111 ± 0.3042 |
| Change in Tg 36 Months post-transplant (n=15,21) | 0.527 ± 0.9968 | -0.385 ± 0.7824 |
Fasting plasma glucose. Change = value at month x post-transplant - pre-conversion baseline values.
| mmol/L | Tacrolimus Then Sirolimus With Mycophenolate/Prednisone | Tacrolimus With Mycophenolate/Prednisone |
|---|---|---|
| Change at 12 Months post-transplant (n=23,33) | 0.606 ± 2.9461 | -0.083 ± 1.7377 |
| Change at 24 Months post-transplant (n=19,31) | 0.832 ± 2.2068 | -0.076 ± 2.3982 |
| Change at 36 Months post-transplant (n=14,22) | 0.686 ± 2.3559 | -0.214 ± 1.8239 |
Fasting insulin. Change = value at month x post-transplant - pre-conversion baseline.
| picomole/liter (pmol/L) | Tacrolimus Then Sirolimus With Mycophenolate/Prednisone | Tacrolimus With Mycophenolate/Prednisone |
|---|---|---|
| Change at 12 Months post-transplant (n=16,23) | -4.549 ± 69.2139 | 17.953 ± 151.0513 |
| Change at 24 Months post-transplant (n=13,23) | -6.120 ± 124.5500 | 32.180 ± 168.4674 |
| Change at 36 Months post-transplant (n=10,14) | -22.759 ± 79.8717 | -2.731 ± 37.6576 |
HbA1C, change = value at month x post-transplant - pre-conversion baseline.
| percentage of glucose | Tacrolimus Then Sirolimus With Mycophenolate/Prednisone | Tacrolimus With Mycophenolate/Prednisone |
|---|---|---|
| Change at 12 Months post-transplant (n=23,26) | 0.008 ± 0.0176 | 0.001 ± 0.0175 |
| Change at 24 Months post-transplant (n=17,25) | 0.009 ± 0.0161 | 0.006 ± 0.0200 |
| Change at 36 Months post-transplant (n=14,16) | 0.012 ± 0.0208 | -0.001 ± 0.0232 |
Adiponectin is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates less risk. Change = month x post-transplant values - pre-conversion baseline values.
| microgram per milliliter (µg/mL) | Tacrolimus Then Sirolimus With Mycophenolate/Prednisone | Tacrolimus With Mycophenolate/Prednisone |
|---|---|---|
| Change at 12 Months post-transplant (n=23,33) | 5.352 ± 5.8935 | -2.205 ± 8.2503 |
| Change at 24 Months post-transplant (n=18,31) | 2.244 ± 7.3628 | -0.267 ± 6.6144 |
| Change at 36 Months post-transplant (n=15,22) | 1.487 ± 6.0933 | -1.413 ± 8.8053 |
hsCRP is a biomarker of cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.
| mg/L | Tacrolimus Then Sirolimus With Mycophenolate/Prednisone | Tacrolimus With Mycophenolate/Prednisone |
|---|---|---|
| Change at 12 Months post-transplant (n=23,33) | 1.611 ± 9.7219 | 1.379 ± 6.7680 |
| Change at 24 Months post-transplant (n=18,31) | -0.563 ± 4.8347 | 1.723 ± 7.6259 |
| Change at 36 Months post-transplant (n=15,22) | 0.336 ± 11.3537 | 3.164 ± 12.5660 |
TNF-alpha is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.
| pg/mL | Tacrolimus Then Sirolimus With Mycophenolate/Prednisone | Tacrolimus With Mycophenolate/Prednisone |
|---|---|---|
| Change at 12 Months post-transplant (n=23,32) | 0.991 ± 6.3462 | 0.000 ± 0.0000 |
| Change at 24 Months post-transplant (n=18,30) | -0.367 ± 1.5580 | 1.894 ± 10.3720 |
| Change at 36 Months post-transplant (n=15,22) | -0.441 ± 1.7067 | 0.000 ± 0.0000 |
Endothelin-1 is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates greater risk. Change = month x post-transplant values - pre-conversion baseline values.
| pg/mL | Tacrolimus Then Sirolimus With Mycophenolate/Prednisone | Tacrolimus With Mycophenolate/Prednisone |
|---|---|---|
| Change at 12 Months post-transplant (n=22,30) | 0.294 ± 0.4975 | 0.028 ± 0.4020 |
| Change at 24 Months post-transplant (n=18,30) | 0.426 ± 0.5376 | 0.138 ± 0.8367 |
| Change at 36 Months post-transplant (n=14,22) | 0.411 ± 0.7316 | -0.104 ± 0.7767 |
IL-6 is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion values.
| pg/mL | Tacrolimus Then Sirolimus With Mycophenolate/Prednisone | Tacrolimus With Mycophenolate/Prednisone |
|---|---|---|
| Change at 12 Months post-transplant (n=23,32) | -0.239 ± 3.6820 | 0.463 ± 3.8100 |
| Change at 24 Months post-transplant (n=18,29) | 0.128 ± 6.9315 | 0.783 ± 4.7295 |
| Change at 36 Months post-transplant (n=15,22) | -0.800 ± 3.8270 | 0.164 ± 6.4529 |
Homocysteine is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.
| micromole/liter (µmol/L) | Tacrolimus Then Sirolimus With Mycophenolate/Prednisone | Tacrolimus With Mycophenolate/Prednisone |
|---|---|---|
| Change at 12 Months post-transplant (n=23,33) | 1.278 ± 3.5572 | 0.530 ± 4.6244 |
| Change at 24 Months post-transplant (n=19,31) | 1.316 ± 4.5373 | 2.158 ± 5.8978 |
| Change at 36 Months post-transplant (n=15,22) | 1.087 ± 4.6641 | 2.459 ± 5.3116 |
Lipoprotein(a) is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.
| milligram per deciliter (mg/dL) | Tacrolimus Then Sirolimus With Mycophenolate/Prednisone | Tacrolimus With Mycophenolate/Prednisone |
|---|---|---|
| Change at 12 Months post-transplant (n=23,30) | 13.496 ± 23.3557 | -11.680 ± 77.1386 |
| Change at 24 Months post-transplant (n=18,26) | 12.517 ± 36.8868 | 6.073 ± 31.5608 |
| Change at 36 Months post-transplant (n=13,17) | 11.885 ± 49.4868 | 6.547 ± 22.0615 |
Fibrinogen is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.
| gram per liter (g/L) | Tacrolimus Then Sirolimus With Mycophenolate/Prednisone | Tacrolimus With Mycophenolate/Prednisone |
|---|---|---|
| Change at 12 Months post-transplant (n=22,31) | 0.62 ± 0.778 | 0.20 ± 0.769 |
| Change at 24 Months post-transplant (n=19,29) | 0.45 ± 0.777 | 0.33 ± 0.741 |
| Change at 36 Months post-transplant (n=14,20) | 0.40 ± 0.557 | 0.21 ± 0.740 |
Vitamin B12 is a biomarker for cardiovascular disease and atherosclerosis risk. A lower level indicates a greater risk. Change = month x post-transplant values - pre-conversion values.
| pmol/L | Tacrolimus Then Sirolimus With Mycophenolate/Prednisone | Tacrolimus With Mycophenolate/Prednisone |
|---|---|---|
| Change at 12 Months post-transplant (n=21,33) | -10.21 ± 161.662 | -11.38 ± 146.530 |
| Change at 24 Months post-transplant (n=19,29) | -36.23 ± 88.910 | -27.46 ± 134.595 |
| Change at 36 Months post-transplant (n=14,21) | -40.00 ± 135.353 | -46.39 ± 183.283 |
Uric Acid is a biomarker for cardiovascular disease and atherosclerosis risk. A higher level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.
| µmol/L | Tacrolimus Then Sirolimus With Mycophenolate/Prednisone | Tacrolimus With Mycophenolate/Prednisone |
|---|---|---|
| Change at 12 Months post-transplant (n=23,33) | -51.53 ± 68.987 | 11.10 ± 89.871 |
| Change at 24 Months post-transplant (n=19,31) | -29.02 ± 93.350 | 3.89 ± 85.439 |
| Change at 36 Months post-transplant (n=15,22) | -19.03 ± 83.162 | -0.58 ± 99.831 |
Folate is a biomarker for cardiovascular disease and atherosclerosis risk. A lower level indicates a greater risk. Change = month x post-transplant values - pre-conversion baseline values.
No measurements were reported for this outcome.
Participants who reported "yes" for taking lipid lowering therapies as concomitant medication.
| participants | Tacrolimus Then Sirolimus With Mycophenolate/Prednisone | Tacrolimus With Mycophenolate/Prednisone |
|---|---|---|
| From consent to conversion | 13 | 24 |
| From conversion to Month 12 | 22 | 29 |
| From Months 12 to Month 24 | 23 | 28 |
| From Months 24 to Month 36 | 18 | 27 |
Participants who reported "yes" for taking anti-hypertensive medications as concomitant medication.
| participants | Tacrolimus Then Sirolimus With Mycophenolate/Prednisone | Tacrolimus With Mycophenolate/Prednisone |
|---|---|---|
| From consent to conversion | 19 | 30 |
| From conversion to Month 12 | 21 | 30 |
| From Months 12 to Month 24 | 21 | 30 |
| From Months 24 to Month 36 | 18 | 28 |
Within-subject annual change rate in TPV in the left and right distal common carotid arteries from the pre-conversion baseline to 18, 24 and 36 months post kidney transplant as determined by ultrasound. Annual change rate equals (=) (TPV at month 18, 24 and 36 post-transplant minus \[-\] TPV at pre-conversion baseline) divided (/) by imaging interval in years. TPV is the sum of assessment in left and right distal common carotid arteries.
| mmˆ3/year | Tacrolimus Then Sirolimus With Mycophenolate/Prednisone | Tacrolimus With Mycophenolate/Prednisone |
|---|---|---|
| Month 18 post-transplant (n=12,12) | 17.15 ± 92.151 | 19.71 ± 44.734 |
| Month 24 post-transplant (n=11,14) | 25.28 ± 67.393 | 9.10 ± 39.707 |
| Month 36 post-transplant (n=7,11) | 6.62 ± 66.240 | 8.98 ± 25.505 |
Collected over From post-conversion to the end of the study (Month 36 post-transplant). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tacrolimus Then Sirolimus With Mycophenolate/Prednisone | — | 17/37 (45.9%) | 36/37 (97.3%) |
| Tacrolimus With Mycophenolate/Prednisone | — | 21/35 (60%) | 33/35 (94.3%) |
| Event | Tacrolimus Then Sirolimus With Mycophenolate/Prednisone | Tacrolimus With Mycophenolate/Prednisone |
|---|---|---|
| INFECTIONGeneral disorders | 2/37 | 3/35 |
| CELLULITISGeneral disorders | 0/37 | 2/35 |
| HERNIAGeneral disorders | 1/37 | 2/35 |
| IMMUNE SYSTEM DISORDERGeneral disorders | 2/37 | 2/35 |
| VIRAL INFECTIONGeneral disorders | 2/37 | 2/35 |
| ARTERIOSCLEROSISCardiac disorders | 0/37 | 2/35 |
| GASTROINTESTINAL HEMORRHAGEGastrointestinal disorders | 0/37 | 2/35 |
| VOMITINGGastrointestinal disorders | 0/37 | 2/35 |
| PNEUMONIARespiratory, thoracic and mediastinal disorders | 1/37 | 2/35 |
| SINUSITISRespiratory, thoracic and mediastinal disorders | 0/37 | 2/35 |
| Event | Tacrolimus Then Sirolimus With Mycophenolate/Prednisone | Tacrolimus With Mycophenolate/Prednisone |
|---|---|---|
| HYPERLIPEMIAMetabolism and nutrition disorders | 14/37 | 5/35 |
| PERIPHERAL EDEMAMetabolism and nutrition disorders | 13/37 | 6/35 |
| ACCIDENTAL INJURYGeneral disorders | 9/37 | 5/35 |
| INFECTIONGeneral disorders | 9/37 | 7/35 |
| HYPERCHOLESTEREMIAMetabolism and nutrition disorders | 9/37 | 2/35 |
| ALBUMINURIARenal and urinary disorders | 9/37 | 2/35 |
| BACK PAINGeneral disorders | 4/37 | 7/35 |
| PAINGeneral disorders | 7/37 | 7/35 |
| VIRAL INFECTIONGeneral disorders | 4/37 | 7/35 |
| ANEMIABlood and lymphatic system disorders | 4/37 | 7/35 |
| Age Continuous(years) | Tacrolimus Then Sirolimus With Mycophenolate/Prednisone | Tacrolimus With Mycophenolate/Prednisone | Total |
|---|---|---|---|
| Mean | 55.8 ± 11.11 | 55.5 ± 11.08 | 55.7 ± 11.02 |
| Sex: Female, Male(Participants) | Tacrolimus Then Sirolimus With Mycophenolate/Prednisone | Tacrolimus With Mycophenolate/Prednisone | Total |
|---|---|---|---|
| Female | 11 | 9 | 20 |
| Male | 26 | 26 | 52 |
The record gives a start of Apr 2006, a primary completion of Dec 2010 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
Results were first posted in May 2012, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sirolimus